Objective: To assess preliminarily the effectiveness
of acamprosate in binge eating disorder (BED).
Not exact matches
An analysis
of more than 120 studies that examined the effectiveness
of medications to treat alcohol use disorders reports that
acamprosate and oral naltrexone show the strongest evidence for decreasing alcohol consumption, according to a study in the May 14 issue
of JAMA.
Because
of its long - standing availability (from the 1950s), clinicians may be more familiar with disulfiram than naltrexone or
acamprosate.
Results: While
acamprosate was not associated with a significantly greater rate
of reduction in binge eating episode frequency or any other measure in the primary longitudinal analysis, in the endpoint analysis it was associated with statistically significant improvements in binge day frequency and measures
of obsessive - compulsiveness
of binge eating, food craving, and quality
of life.